Overview

Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
0
Participant gender:
All
Summary
This non-inferiority study will assess safety and efficacy of LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) versus DuoTrav® (travoprost 0.004%/timolol 0.5% combination ophthalmic solution) in patients previously on Travatan® Z (travoprost ophthalmic solution 0.004%) monotherapy.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost
Cloprostenol
Ophthalmic Solutions
Pharmaceutical Solutions
Timolol
Travoprost
Criteria
Inclusion Criteria:

- Open angle glaucoma or ocular hypertension

- Best corrected visual acuity of 20/100 or better in both eyes

Exclusion Criteria:

- Ocular surgery within 3 months, or anticipated ocular surgery within 12 weeks

- Previous treatment with LUMIGAN® RC or DuoTrav®

- History of LASIK, LASEK, RK or PRK in the study eye(s)

- Active ocular inflammation